Cargando…

Evaluation of the Pharmacokinetics and Safety of a Single Oral Dose of Fasiglifam in Subjects with Normal or Varying Degrees of Impaired Renal Function

INTRODUCTION: Approximately one-third of patients with type 2 diabetes mellitus (T2DM) have concurrent renal impairment. There are limited therapeutic options for these patients. Fasiglifam is a G protein-coupled receptor 40 agonist that was under investigation for the treatment of T2DM. The objecti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mayer, Michael, Nudurupati, Sai, Peng, Xuejun, Marcinak, John
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2014
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4269813/ https://www.ncbi.nlm.nih.gov/pubmed/25374042 http://dx.doi.org/10.1007/s40268-014-0066-4

Ejemplares similares

Evaluation of the Pharmacokinetics and Safety of a Single Oral Dose of Fasiglifam in Subjects with Mild or Moderate Hepatic Impairment
por: Marcinak, John, et al.
Publicado: (2018)

Pharmacokinetics and Safety of a Single Oral Dose of Mirogabalin in Japanese Subjects With Varying Degrees of Renal Impairment
por: Kato, Manabu, et al.
Publicado: (2017)

Pharmacokinetics of intravenous telavancin in healthy subjects with varying degrees of renal impairment
por: Worboys, Philip D., et al.
Publicado: (2015)

Safety and pharmacokinetics of SPR206 in subjects with varying degrees of renal impairment
por: Bruss, Jon B., et al.
Publicado: (2023)

2130. Safety and Pharmacokinetics of SPR206 in Subjects with Varying Degrees of Renal Impairment
por: Bruss, Jon, et al.
Publicado: (2023)

Delafloxacin Pharmacokinetics in Subjects With Varying Degrees of Renal Function
por: Hoover, Randall K., et al.
Publicado: (2017)

Effect of Varying Degrees of Renal Impairment on the Pharmacokinetics of Omecamtiv Mecarbil
por: Trivedi, Ashit, et al.
Publicado: (2021)

Pharmacokinetics of Oral Tebipenem Pivoxil Hydrobromide in Subjects with Various Degrees of Renal Impairment
por: Patel, Gina, et al.
Publicado: (2022)

Pharmacokinetics of a Single Oral Dose of the MEK1/2 Inhibitor Selumetinib in Subjects With End‐Stage Renal Disease or Varying Degrees of Hepatic Impairment Compared With Healthy Subjects
por: Dymond, Angela W., et al.
Publicado: (2016)

Pharmacokinetics and pharmacodynamics of oral tolvaptan in patients with varying degrees of renal function
por: Shoaf, Susan E, et al.
Publicado: (2014)

Clinical Pharmacokinetics of Sulfobutylether‐β‐Cyclodextrin in Patients With Varying Degrees of Renal Impairment
por: Hoover, Randall K., et al.
Publicado: (2018)

Pharmacokinetics and pharmacodynamics of an orally disintegrating tablet formulation of dexlansoprazole
por: Kukulka, Michael, et al.
Publicado: (2016)

Pharmacokinetics of the Long‐Acting Basal Insulin LY2605541 in Subjects With Varying Degrees of Renal Function
por: Linnebjerg, Helle, et al.
Publicado: (2016)

Evaluation of the Single-dose Pharmacokinetics of Bilastine in Subjects with Various Degrees of Renal Insufficiency
por: Lasseter, Kenneth C., et al.
Publicado: (2013)

Pharmacokinetics and Safety of a Single Oral Dose of Peficitinib (ASP015K) in Japanese Subjects with Normal and Impaired Renal Function
por: Miyatake, Daisuke, et al.
Publicado: (2019)

Population Pharmacokinetics of Ceftolozane/Tazobactam in Healthy Volunteers, Subjects With Varying Degrees of Renal Function and Patients With Bacterial Infections
por: Chandorkar, Gurudatt, et al.
Publicado: (2015)

A Phase 1 Study To Assess the Pharmacokinetics of Intravenous Plazomicin in Adult Subjects with Varying Degrees of Renal Function
por: Komirenko, Allison S., et al.
Publicado: (2018)

Safety and Pharmacokinetics of Taniborbactam (VNRX-5133) with Cefepime in Subjects with Various Degrees of Renal Impairment
por: Dowell, James A., et al.
Publicado: (2022)

Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects with Renal Impairment
por: Granhall, Charlotte, et al.
Publicado: (2018)

Real-World Experience With Higher-Than-Recommended Doses of Lamivudine in Patients With Varying Degrees of Renal Impairment
por: Fischetti, Briann, et al.
Publicado: (2018)

Evaluation of pharmacokinetics and safety of talazoparib in patients with advanced cancer and varying degrees of hepatic impairment
por: Guo, Cen, et al.
Publicado: (2022)

Pharmacokinetics, Pharmacodynamics, and Safety of Peginterferon Beta-Ia in Subjects with Normal or Impaired Renal Function
por: Hu, Xiao, et al.
Publicado: (2015)

Single‐dose Pharmacokinetics of Eluxadoline in Healthy Participants With Normal Renal Function and Participants With Renal Impairment
por: Boinpally, Ramesh, et al.
Publicado: (2022)

Pharmacokinetics and Safety of a Single Oral Dose of Peficitinib (ASP015K) in Japanese Subjects With Normal and Impaired Hepatic Function
por: Miyatake, Daisuke, et al.
Publicado: (2019)

Vancomycin population pharmacokinetics analysis in Chinese paediatric patients with varying degrees of renal function and ages: development of new practical dosing recommendations
por: Chen, Jihui, et al.
Publicado: (2023)

Pharmacokinetics of Cabotegravir in Subjects with Severe Renal Impairment
por: Parasrampuria, Ridhi, et al.
Publicado: (2017)

Pharmacokinetics and safety of dexlansoprazole MR in pediatric patients with symptomatic gastroesophageal reflux disease
por: Kukulka, Michael, et al.
Publicado: (2014)

Pharmacokinetics and pharmacodynamics of ticagrelor in subjects on hemodialysis and subjects with normal renal function
por: Teng, Renli, et al.
Publicado: (2018)

A Novel Antidiabetic Drug, Fasiglifam/TAK-875, Acts as an Ago-Allosteric Modulator of FFAR1
por: Yabuki, Chiori, et al.
Publicado: (2013)

2144. A Phase 1, Multicenter, Open-Label, Parallel-Group Study to Assess the Safety and Pharmacokinetics (PK) of Oral Epetraborole Tablets in Adult Subjects with Varying Degrees of Renal Function
por: Patel, Gina, et al.
Publicado: (2023)

Single-Dose Pharmacokinetics of Milvexian in Participants with Normal Renal Function and Participants with Moderate or Severe Renal Impairment
por: Perera, Vidya, et al.
Publicado: (2022)

Evaluation of the Pharmacokinetics and Renal Excretion of Simeprevir in Subjects with Renal Impairment
por: Ouwerkerk-Mahadevan, Sivi, et al.
Publicado: (2015)

Pharmacokinetics of Gepotidacin in Subjects With Normal Hepatic Function and Hepatic Impairment
por: Hossain, Mohammad, et al.
Publicado: (2021)

Pharmacokinetics and Safety of Omadacycline in Subjects with Impaired Renal Function
por: Berg, Jolene K., et al.
Publicado: (2018)

Pharmacokinetics of renally excreted drug dexpramipexole in subjects with impaired renal function
por: He, Ping, et al.
Publicado: (2014)

An open-label study to estimate the effect of steady-state erythromycin on the pharmacokinetics, pharmacodynamics, and safety of a single dose of rivaroxaban in subjects with renal impairment and normal renal function
por: Moore, Kenneth T, et al.
Publicado: (2014)

Pharmacokinetics (PK) of Eravacycline in Subjects with Renal or Hepatic Impairment Compared with Healthy Subjects
por: Horn, Patrick, et al.
Publicado: (2017)

Pharmacokinetics of dolutegravir in HIV-seronegative subjects with severe renal impairment
por: Weller, Stephen, et al.
Publicado: (2013)

Pharmacokinetics and safety of revefenacin in subjects with impaired renal or hepatic function
por: Borin, Marie T, et al.
Publicado: (2019)

Pharmacokinetics of Oral Nirmatrelvir/Ritonavir, a Protease Inhibitor for Treatment of COVID‐19, in Subjects With Renal Impairment
por: Toussi, Sima S., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_q91up0eo1lga6uncqfq5hs442q